chemical:semaglutide
After two months, Novo Nordisk and HIMS part ways
Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.
GLP1.Guide Staff
Scouring sources for information on GLP1 Agonist drugs, so you don't have to.
category:news
Preserving muscle: GLP1s with Bimagrumab
We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.
company:novo-nordisk
Novo Nordisk patent protections lapse in Canada
Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.
category:news
A challenge to Eli Lilly's Tirzepatide patent
Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.
drug:eloralinitide
Amylin, with and without GLP1: Eloralinitide
We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.
category:side-effects
Ozempic is not likely to directly enlarge the male appendage.
A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.
company:eli-lilly
Eli Lilly's big Summer 2025 update
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
research
Semaglutide vs Tirzepatide (Clinical trial)
Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.
company:roche
Roche and Carmot's GLP1 pipeline
We take a look at Roche (via Carmot)'s GLP1 pipeline development, and figure out how CT-388, CT-996, and CT-868 are trending.
category:news
A new risk: Kidney Cancer
New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.
malady:addiction
GLP1s vs. Addiction, a quick review
We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.
drug:retatrutide
An update on Retatrutide (May 2025)
We take some time to check in on Retatrutide -- an update on how research and trials are progressing, and relevant news.